Research Paper Volume 13, Issue 5 pp 6982—6998
Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment
Figure 6. The anti-cancer mechanisms of Zeta55 in prostate cancer. First, Zeta55 prevents androgens from binding AR, leading to AR inactivation. Second, Zeta55 inhibits the deacetylation activity of HDAC6, which regulates cell proliferation, metastasis, invasion, and mitosis. Third, Zeta55 promotes AR degradation through its HDAC6 inhibitor activity.